XBiotech Inc. develops True Human™ monoclonal antibodies derived from human donors for inflammatory, oncology, neurologic, and infectious disease applications. Company news centers on its antibody platform, Natrunix, an anti-interleukin-1alpha candidate studied in pancreatic cancer and rheumatology, and Hutrukin, a candidate therapy for reducing brain injury after ischemic stroke.
Recurring developments include clinical study results, program-prioritization decisions, FDA-related clinical authorizations, enrollment updates, and the company’s Austin campus operations, including GMP manufacturing, research laboratories, infectious disease facilities, quality control, and clinical operations.
XBiotech (XBIT) elected Jan-Paul Simard as Co-Chief Executive Officer alongside Dr. Sushma Shivaswamy, effective October 23, 2026.
Shivaswamy became interim CEO in December 2025 following founder John Simard's retirement. She was appointed Chief Scientific Officer in 2017 and oversaw scientific and technical operations from research and development through antibody production. Jan-Paul Simard joined XBiotech as a research and development assistant in 2012 and moved to clinical development in 2020, contributing to study design and protocol development across cancer, osteoarthritis and rheumatoid arthritis trials.
XBiotech (XBIT) announced final Phase II TASKIN results meeting the trial’s prespecified primary efficacy success criterion in refractory metastatic colorectal cancer. The randomized study tested vilamakitug added to trifluridine/tipiracil, with or without bevacizumab. At 12 months, 49 of 80 evaluable experimental-arm patients (61.3%) were alive, exceeding the required 42 survivors; control survival was 44 of 79 (55.7%).
The 12-month rate of remaining on a viable treatment strategy was 31.2% versus 20.3% (p = 0.17). Median time without disease progression was 5.9 versus 5.6 months (p = 0.42). A prospective exploratory analysis of 37 patients with right-sided tumors found a 62% lower risk of death versus control through 12 months. Mean trifluridine/tipiracil compliance was 96.4%; permanent discontinuation of vilamakitug/placebo was 1.3%. XBiotech said the findings guide its advance toward registrational clinical development.
XBiotech (NASDAQ:XBIT) announced FDA clearance to begin the Phase II V-SPINE (PT064) trial of vilamakitug in active axial spondyloarthritis. The IND completed the FDA’s 30-day review without clinical hold, allowing U.S. patient enrollment and marking the resumption of XBiotech’s rheumatology program under a leading expert advisory board.
XBiotech (NASDAQ: XBIT) announced the suspension of its rheumatology clinical program following irregularities in its Phase II study of Natrunix for Rheumatoid Arthritis. The study, which enrolled approximately 230 subjects with moderate to severe rheumatoid arthritis, failed to meet its primary endpoint of ACR20 response rate after 12 weeks. The trial evaluated Natrunix (200mg or 400mg weekly) in combination with methotrexate (MTX) against placebo with MTX.
Significant irregularities were discovered at the highest enrolling clinical sites, including multiple enrollments of the same subjects, raising concerns about data interpretation. The company has put additional planned studies in arthritis and ankylosing spondylitis on hold while evaluating these findings.
XBiotech (NASDAQ: XBIT) announced promising results from its Phase 1/2 trial for advanced pancreatic cancer treatment using Natrunix in combination with a standard chemotherapy regimen. The study, titled 1-BETTER, enrolled 65 subjects who received either the Natrunix combination or a placebo. Key findings include a 28% reduction in significant adverse events in the Natrunix group, a 33% decrease in hospitalization days, and a notable improvement in patient-reported outcomes such as reduced fatigue (22%) and pain (41%). While overall survival rates showed a trend favoring Natrunix, the small sample size led to a borderline statistical significance (p = 0.096). XBiotech emphasizes the potential of Natrunix to improve tolerability and efficacy of pancreatic cancer treatment.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.